Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

108.47 -2.02 (-1.82%)
Streaming Delayed Price Updated: 11:33 AM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
3 No-Brainer Stocks to Buy With $500 Right Now
You don't need a mountain of cash to build wealth on Wall Street. 
Via The Motley Fool
Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use
Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis. 
Via Benzinga
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
Pot Stocks: Values Or Traps?
Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses. 
Via The Motley Fool
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50 
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
Luxembourg: Medical Marijuana Shortage Due To Supplier Change 
Via Benzinga
Topics Cannabis Supply Chain
Exposures Cannabis Supply Chain
Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio
On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale. 
Via Benzinga
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
These highly profitable, time-tested companies can deliver for their shareholders in any economic climate. 
Via The Motley Fool
4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
3 Cannabis Stocks That Should Be on Every Investor’s Radar This Fall
The cannabis industry is a quiet place where huge upside potential is building up. As more regions legalize, cannabis stocks can soar. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
Cannabis stocks re seeing renewed interest and these seven look like reasonable buys as rescheduling approaches for weed. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Industry Changes As Marijuana Rescheduling Looms
As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.